keyword
MENU ▼
Read by QxMD icon Read
search

Leukemia

keyword
https://www.readbyqxmd.com/read/29031074/synthesis-antiproliferative-anti-tubulin-activity-and-docking-study-of-new-1-2-4-triazoles-as-potential-combretastatin-analogues
#1
Muhamad Mustafa, Dalia Abdelhamid, ElShimaa M N Abdelhafez, Mahmoud A A Ibrahim, Amira M Gamal-Eldeen, Omar M Aly
Combretastatin A4 (CA4) is a natural product characterized by a powerful inhibition of tubulin polymerization and a potential anticancer activity. However, therapeutic application of CA4 is substantially hindered due to geometric isomerization. In the current study, new cis-restricted Combretastatin A4 analogues containing 1,2,4-triazle in place of the olefinic bond were designed and synthesized. The synthesized compounds were evaluated for their in vitro antiproliferative activity in human hepatocellular carcinoma HepG2 and leukemia HL-60 cell lines using MTT assay...
September 28, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29029365/eighteen-month-lamivudine-prophylaxis-on-preventing-occult-hepatitis-b-virus-hbv-infection-reactivation-in-patients-with-hematologic-malignancies-receiving-immunosuppression-therapy
#2
Aldo Marrone, Nicolina Capoluongo, Chiara D'Amore, Mariantonietta Pisaturo, Mariarosaria Esposito, Salvatore Guastafierro, Isabella Siniscalchi, Margherita Macera, Adriana Boemio, Lorenzo Onorato, Luca Rinaldi, Carmine Minichini, Luigi Elio Adinolfi, Evangelista Sagnelli, Lucia Mastrullo, Nicola Coppola
This study evaluated the long-term efficacy and safety of an 18-month lamivudine prophylaxis in 68 HBsAg-negative/anti-HBc-positive patients with onco-hematological disease. All 68 consecutive HBsAg-negative/anti-HBc-positive patients with an onco-hematological disease and naïve for chemotherapy observed from April 2008 to December 2012 at two Hematology Units in Naples were treated with lamivudine for 18 months after stopping chemotherapy and monitored for HBsAg at months 1 and 3 during chemotherapy and then every three months after its discontinuation...
October 13, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29028530/a-pentanoic-acid-derivative-targeting-matrix-metalloproteinase-2-mmp-2-induces-apoptosis-in-a-chronic-myeloid-leukemia-cell-line
#3
Avinaba Mukherjee, Nilanjan Adhikari, Tarun Jha
Depending on our previous observations, some compounds of pentanoic acid were designed and synthesized. Characterization of the synthesized compounds was done by mass, NMR and IR spectroscopy as well as elemental analysis. Among the synthesized molecules, (2S)-5-oxo-2-[(nitrobenzene-4-yl sulfonyl) amino]-5-(pentylamino) pentanoic acid (Cpd 11) was found as a lead and potent inhibitor of matrix metalloproteinase-2 (MMP-2). Molecular modeling and enzyme inhibition studies were done to confirm the interaction or inhibitory potential of this compound...
September 27, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29028392/application-of-selected-reaction-monitoring-and-parallel-reaction-monitoring-for-investigation-of-hl-60-cell-line-differentiation
#4
Svetlana E Novikova, Olga V Tikhonova, Leonid K Kurbatov, Tatiana E Farafonova, Igor V Vakhrushev, Victor G Zgoda
Targeted mass spectrometry represents a powerful tool for investigation of biological processes. The convenient approach of selected reaction monitoring using stable isotope-labeled peptide standard (SIS) is widely applied for protein quantification. Along with this method, high-resolution parallel reaction monitoring has been increasingly used for protein targeted analysis. Here we applied two targeted approaches (selected reaction monitoring with SIS and label-free parallel reaction monitoring) to investigate expression of 11 proteins during all-trans retinoic acid-induced differentiation of HL-60 cells...
August 2017: European Journal of Mass Spectrometry
https://www.readbyqxmd.com/read/29027959/radiation-induced-changes-of-microrna-expression-profiles-in-radiosensitive-and-radioresistant-leukemia-cell-lines-with-different-levels-of-chromosome-abnormalities
#5
Daria Liamina, Wladimir Sibirnyj, Anna Khokhlova, Viacheslav Saenko, Eugenia Rastorgueva, Aleksandr Fomin, Yury Saenko
In our study, we estimate an effect from chromosome aberrations and genome mutations on changes in microRNA expression profiles in cancer cell lines demonstrating different radiosensitivity. Here, cell viability and microRNA spectrum have been estimated 1, 4, and 24 h after irradiation. MiSeq high-throughput sequencing system (Illumina, San Diego, CA, USA) is employed to perform microRNA spectrum estimation. In the K562 cell line, the number of expressed microRNAs in chromosomes demonstrates a more pronounced variation...
October 13, 2017: Cancers
https://www.readbyqxmd.com/read/29027647/dasatinib-associated-reversible-demyelinating-peripheral-polyneuropathy-in-a-case-of-chronic-myeloid-leukemia
#6
Takashi Ishida, Naoyuki Akagawa, Tomomi Miyata, Naomi Tominaga, Takahiro Iizuka, Masaaki Higashihara, Takahiro Suzuki, Koji Miyazaki
Tyrosine kinase inhibitors (TKIs) are essential for the treatment of chronic myeloid leukemia (CML). Adverse effects of dasatinib have been reported; however, few reports have highlighted the association between dasatinib and demyelinating peripheral neuropathy (DPN). We report a patient with CML who developed acute onset of DPN associated with dasatinib therapy. A 46-year-old Japanese woman was treated with dasatinib for 7 months after the diagnosis of CML and she achieved a major molecular response (MMR)...
October 13, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29027641/cost-effectiveness-of-imatinib-dasatinib-and-nilotinib-as-first-line-treatment-for-chronic-phase-chronic-myeloid-leukemia-in-china
#7
Na Li, Bin Zheng, Hong-Fu Cai, Jing Yang, Xiao-Feng Luo, Li-Zhu Weng, Feng-Mei Zhan, Mao-Bai Liu
BACKGROUND AND OBJECTIVE: Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is high and the medical economic burden of patients with CML on the government is heavy. This study tested the cost effectiveness of imatinib, nilotinib, and dasatinib as first-line treatment in Chinese patients who were first diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP)...
October 13, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29027638/fluconazole-versus-mould-active-triazoles-for-primary-antifungal-prophylaxis-in-adult-patients-with-acute-lymphoblastic-leukemia-clinical-outcome-and-cost-effectiveness-analysis
#8
Yan Wang, Yuanming Xing, Lu Chen, Ti Meng, Ying Li, Jiao Xie, Limei Chen, Yalin Dong, Weihua Dong
This study evaluated the clinical and cost-effectiveness of prophylactic use of fluconazole versus mould-active triazoles (voriconazole and posaconazole) in adult patients with acute lymphoblastic leukemia (ALL). A decision analytical model was developed with inputs from a 7-year retrospective study (2009-2016) of 103 consecutive adult patients with ALL who received antifungal prophylaxis. Information on the administration of antifungal agents, clinical outcomes, and costs were collected. One-way sensitivity analyses and probabilistic sensitivity analysis were performed...
October 13, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29027628/the-prognostic-significance-of-measurable-minimal-residual-disease-in-acute-myeloid-leukemia
#9
REVIEW
Francesco Buccisano, Christopher S Hourigan, Roland B Walter
PURPOSE OF REVIEW: The purpose of this review was to evaluate recent literature on detection methodologies for, and prognostic significance of, measurable ("minimal") residual disease (MRD) in acute myeloid leukemia (AML). RECENT FINDINGS: There is no "one-fits-all" approach to MRD testing in AML. Most exploited to date are methods relying on immunophenotypic aberrancies (identified via multiparameter flow cytometry) or genetic abnormalities (identified via PCR-based assays)...
October 13, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29027574/the-prognostic-significance-of-serum-xcl1-concentration-in-patients-with-acute-lymphoblastic-leukemia-a-pilot-study
#10
Cesar Homero Gutiérrez-Aguirre, Juan Antonio Flores-Jiménez, Julio Alatorre-Ricardo, Olga Graciela Cantú-Rodríguez, Adrián Rosas-Taraco, Rosario Salazar-Riojas, José Carlos Jaime-Pérez, Mónica Sánchez-Cárdenas, Leslie López-Silva, Azalia M Martínez-Castilla, Mario Cesar Salinas-Carmona, David Gómez-Almaguer
There is no information about XCL1 in patients with acute lymphoblastic leukemia (ALL). The objective of this study was to correlate the serum levels of XCL1 and survival in ALL patients. Only ALL patients older than 12 months were considered to participate. Serum XCL1 was measured at diagnosis, end of remission induction, and end of consolidation. Thirty-three ALL patients with median age of 21 years (1-78) were included. Higher XCL1 level (above 50 pg/mL) at ALL diagnosis correlated with higher survival (p = 0...
October 13, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29027261/prognostic-significance-of-additional-chromosomal-abnormalities-at-the-time-of-diagnosis-in-patients-with-chronic-myeloid-leukemia-treated-with-frontline-tyrosine-kinase-inhibitors
#11
Ahmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, Farhad Ravandi, Gautam Borthakur, Courtney DiNardo, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Sherry Pierce, Guillermo Garcia-Manero, William Wierda, Srdan Verstovsek, Elias Jabbour, Jorge Cortes
Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the setting of new tyrosine kinase inhibitors (TKIs) is less well understood. Patients with CML in CP with or without ACA at diagnosis treated with frontline TKIs in prospective clinical trials were analyzed for outcomes. Among 603 patients treated, 29 (5%) had ACA. Patients with ACA included 2 of 72 (2.8%) treated with imatinib 400 mg, 9 of 207 (4...
October 13, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29027254/lymphoplasmacytoid-cytology-in-plasma-cell-leukemia
#12
Ahmad Khoder, Magda Al Obaidi, Natasha Wiles, Elisabet Nadal-Melsio, Barbara J Bain
No abstract text is available yet for this article.
October 13, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29027250/revisiting-the-need-for-bone-marrow-examination-in-chronic-myeloid-leukemia
#13
Ayalew Tefferi, Curtis A Hanson, Rhett P Ketterling
No abstract text is available yet for this article.
October 13, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29027146/correction-to-jsh-guideline-for-tumors-of-hematopoietic-and-lymphoid-tissues-lukemia-4-chronic-myelogenous-leukemia-cml-myeloproliferative-neoplasms-mpn
#14
Noriko Usui
In the original publication of this article, the "Acknowledgements" was not included and it is given below for your reading.
October 12, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29027108/prognostic-value-of-genetic-mutations-in-adolescent-and-young-adults-with-acute-myeloid-leukemia
#15
Yachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, Yasunobu Nagata, Norio Shiba, Yuka Iijima-Yamashita, Akira Shimada, Takao Deguchi, Hayato Miyachi, Akio Tawa, Takashi Taga, Akitoshi Kinoshita, Hideki Nakayama, Nobutaka Kiyokawa, Akiko Moriya Saito, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Yasushi Miyazaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Seishi Ogawa, Tomoki Naoe, Yasuhide Hayashi, Keizo Horibe, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Hitoshi Kiyoi
Clinical outcomes and the genetic background of acute myeloid leukemia (AML) in adolescent and young adults (AYAs) are known to differ in younger children and older adults. To clarify the impact of genetic mutations on clinical outcomes of AYAs with AML, we analyzed data from the JPLSG AML-05 and JALSG AML201 studies. AYAs aged 15-39 years (n = 103) were included. FLT3-ITD, KIT, CEBPA, NRAS, KRAS, WT1, MLL-PTD, and NPM1 mutations were analyzed. Overall survival (OS) of the AYAs was 61% and event-free survival was 38% at 3 years...
October 12, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29026839/missing-the-benefit-of-metformin-in-acute-myeloid-leukemia-a-problem-of-contrast
#16
Alice C Ceacareanu, George K Nimako, Zachary A P Wintrob
OBJECTIVE: To evaluate whether metformin's cancer-related benefits reported in patients with solid tumors (ST) are also present in acute myeloid leukemia (AML) patients. METHODS: Baseline demographic and clinical history for all diabetes mellitus patients newly diagnosed with AML or cancer of the breast, ovary, prostate, gastrointestinal tract, lung, or kidney at Roswell Park Cancer Institute in Buffalo, NY (January 2003-December 2010, n = 924) was collected. Overall survival (OS) and disease-free survival (DFS) were assessed by Kaplan-Meier (KM) analysis and Cox proportional hazards regression (hazard ratio [HR])...
July 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29026712/therapy-related-acute-myeloid-leukemia-following-treatment-for-burkitt-s-lymphoma
#17
Seung-Shin Lee
No abstract text is available yet for this article.
September 2017: Chonnam Medical Journal
https://www.readbyqxmd.com/read/29026552/the-discussion-of-t-1-17-p11-q21-translocation-in-acute-promyelocytic-leukemia-patient-on-molecular-remission
#18
Yannan Jia, Chengwen Li, Jiawei Zhao, Yang Song, Juan Wang, Yingchang Mi
Some chromosomal aberrations emerging in the course of treatment are probably not related to disease progression, but attribute to the germline alteration. Therefore, the dynamic genetic tests should be performed during the whole treatment process, which is significantly essential for efficacy evaluation and treatment decision- making.
October 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/29026321/characteristics-and-mutation-analysis-of-ph-positive-leukemia-patients-with-t315i-mutation-receiving-tyrosine-kinase-inhibitors
#19
Peipei Xu, Dan Guo, Xiaoyan Shao, Miaoxin Peng, Bing Chen
BACKGROUND: TKIs are the first-line treatment for patients with Ph-positive (Ph+) leukemia. However, drug resistance is frequently observed, mainly due to mutations within the breakpoint cluster region-Abelson leukemia virus (BCR-ABL) kinase domain. The T315I substitution confers complete resistance to TKIs. The aim of this study was to analyze the clinical characteristics of 17 patients with T315I mutation after TKI treatment and provide a basis for prognosis. PATIENTS AND METHODS: The clinical data of 17 TKI-resistant Ph+ leukemia patients who were found to have a ABL kinase domain mutation from September 2008 to January 2017 were collected...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29026208/targetable-fusions-of-the-frk-tyrosine-kinase-in-alk-negative-anaplastic-large-cell-lymphoma
#20
G Hu, S Dasari, Y W Asmann, P T Greipp, R A Knudson, H K Benson, Y Li, B W Eckloff, Jin Jen, B K Link, L Jiang, J S Sidhu, L E Wellik, T E Witzig, N N Bennani, J R Cerhan, R L Boddicker, A L Feldman
Leukemia accepted article preview online, 13 October 2017. doi:10.1038/leu.2017.309.
October 13, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
1190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"